

ASX Announcement | 26 February 2026  
**AdAlta Limited (ASX:1AD)**

## **AdCella appoints clinical advisory board**

Clinical leaders in oncology, mesothelioma, CAR-T cell therapies, haematology and immunology to support development of BZDS1901

### **Investment highlights**

- Leading physicians appointed to AdCella's clinical advisory board
- The advisory board brings together all the disciplines needed to design and deliver the first clinical trial of BZDS1901 in Australia

**AdAlta Limited (ASX:1AD)** (“AdAlta” or “the Company”), developer of next generation cell and protein therapeutic products, advises that its subsidiary, AdCella Pty Ltd (“AdCella”) has convened a clinical advisory board to advise on clinical development and Phase 1 trial design of BZDS1901, its mesothelin-targeted, armoured CAR-T cell therapy developed to treat mesothelioma and other solid cancers, including lung and gynaecological malignancies.

### **AdAlta's Consultant Chief Medical Officer, Dr Kevin Lynch said:**

*“Together these eminent clinicians provide leadership and deep expertise in clinical oncology, mesothelioma, solid cancer CAR-T cell therapies, haematology and immunology, disciplines that are all necessary to safely and efficiently deliver BZDS1901 to patients with solid tumours. We are delighted that they have agreed to help us guide the further development of BZDS1901 and to ensure that Australian patients with mesothelioma and other mesothelin-expressing tumors are the first to have access to this potentially ground-breaking therapy outside China.”*

### **Clinical advisory board members bring deep clinical oncology, mesothelioma, immunology, haematology and CAR-T cell therapy expertise**

The role of the clinical advisory board is to review and advise on the clinical trial design for BZDS1901; advise on current and emerging treatment standards to best position BZDS1901 in the mesothelioma treatment algorithm; to identify new and emerging knowledge in mesothelioma and other tumours that may be targeted with BZDS1901; and to provide insights into leading international clinical institutes and thought leaders who can help with subsequent stages of development of the product.



*Assoc Prof Emily Blyth* is a clinical and laboratory haematologist, blood transplant and cell therapies physician. She is the Clinical Lead for the Immune Effector Cell Service at Westmead Hospital and a Principal Research Fellow at University of Sydney and Westmead Institute for Medical Research. Her research is focused on development and clinical application of cell and gene therapies. Assoc Prof Blyth is the ANZ Regional Vice President for the International Society for Cell and Gene Therapy (2024-2026).



*Prof Simon Harrison* is Director of the Centre of Excellence in Cellular Immunotherapy at the Peter MacCallum Cancer Centre (“Peter Mac”), Clinical Lead of the CAR-T and Ambulatory Cellular Therapies Unit (Clinical Haematology, Peter Mac and The Royal Melbourne Hospital) and Honorary Clinical Professor at The University of Melbourne. His clinical research in multiple myeloma examines novel therapies and drug combinations, early phase clinical trial design and cellular immune therapies such as CAR-T. His laboratory research focuses on the development of novel cellular immune therapies in cancer. He is the Chair of the Myeloma Australia Medical and Scientific Advisory Group.



*Prof Ben Solomon* is a Medical Oncologist at the Peter MacCallum Cancer Centre in Melbourne. Ben is involved in practice-changing lung cancer clinical trials including trials leading to the registration of multiple lung cancer drugs. He has more than 200 peer-reviewed publications including “real world” clinical outcomes research in mesothelioma, was a founding board member of TOGA, was elected to the International Association for the Study of Lung Cancer (IASLC) Board in 2023, and is a Board member of the Cancer Council of Victoria. He was Principal Investigator on one of the first solid cancer CAR-T clinical trials at the Peter Mac.



*Assoc Prof Ben Tran* is a medical oncologist at Peter MacCallum Cancer Centre where he leads the genitourinary medical oncology group and solid cancer CAR-T clinical trials program. As a Senior Clinical Research Fellow at the Walter & Eliza Hall Institute, Melbourne, Ben leads multi-national (including Asia) registries in genitourinary cancers that have been utilized to describe treatment patterns, identify clinical and tissue-based biomarkers and inform future research strategies. He is globally respected for his knowledge and expertise in early phase, first time in human clinical trials and chairs the Phase 1 Trials Group within Cancer Trials Australia and the Germ Cell Tumour group within the ANZ Urogenital and Prostate Cancer Trials Group.

AdCella anticipates additional members will join the clinical advisory board in future.

To view a summary and engage in discussion about this announcement visit AdAlta’s InvestorHub here: <https://investorhub.adalta.com.au/link/P2Abzr>

This ASX announcement has been authorised for release by the Board of AdAlta Limited (ASX:1AD).

**For further information, please contact:**

**AdAlta Limited (ASX:1AD)**

Tim Oldham  
CEO & Managing Director  
P: +61 403 446 665  
E: [ir@adalta.com.au](mailto:ir@adalta.com.au)

**About AdAlta**

AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers.

Through its subsidiary company, AdCella Pty Ltd’s ‘East to West’ strategy, the Company is integrating Asia’s prowess in T cell therapy development with the efficiency and quality of Australia’s clinical and manufacturing ecosystem to create a pathway connecting ‘Eastern’ innovation in cellular immunotherapies with ‘Western’ regulated markets and patients.

AdCella in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies with potential to position each product for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialization.

AdCella implements a disciplined approach to asset selection focused on highly differentiated T cell therapy products supported by clinical data in solid cancers. The company adopts a capital efficient business model delivering a rapid return on investment in each project that is replicable and provides opportunities to scale across multiple products.

Solid tumours account for 90% of cancers yet remain underserved by current cellular immunotherapies. AdCella aims to dominate this high-growth segment. The cellular immunotherapy market is projected to grow at a compound annual growth rate of 34% to reach US\$20.3 billion by 2028.

AdCella’s first asset, BZDS1901, is a first in class CAR-T cell therapy for mesothelioma and other solid cancers including lung and gynaecological cancers. BZDS1901 is the first CAR-T product for mesothelioma to secrete

its own immune checkpoint inhibitor “armouring” to help overcome tumour immune suppression, is manufactured in less than two days without expensive viral vectors, and has demonstrated clinical potential, including difficult to achieve complete responses in advanced mesothelioma in China.

Separately, AdAlta’s first in class fusion protein, AD-214, takes a whole new approach to fibrotic diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis. Following demonstration of efficacy in multiple animal models of disease and two successful Phase I clinical studies, AD-214 is available for partnering. AdAlta’s first in class i-body®, WD-34, is a discovery stage asset being advanced through partnering as a potentially transformational prophylaxis and treatment for malaria.

To learn more, please visit: [www.adalta.com.au](http://www.adalta.com.au)

### For more information



Join our [InvestorHub](#)



Follow us on [LinkedIn](#)



Follow us on [X \(formerly Twitter\)](#)